Cftr Trikafta denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Trikafta as Not FDA-Approved

A "not FDA-approved" denial means the reviewer concluded that the requested use—for this patient's specific mutation, age group, or clinical context—falls outside the FDA-approved labeling as Aetna interprets it. This is distinct from an experimental denial: the drug itself is FDA-approved, but Aetna is asserting that your specific application is outside the approved indication.

This denial most commonly occurs when a patient's mutation is rare or falls into a genotype class added to the FDA label in a later approval cycle that Aetna's policy has not yet incorporated, or when there is an ambiguity in how the mutation was reported in the prior-auth submission.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your denial notice. Specifically request the clinical policy document Aetna used, the page and section citing the "not approved" finding, and the specialty of the reviewing clinician.
• External review (ACA §2719 / ERISA §503): An independent external reviewer will evaluate this against the actual FDA label—not Aetna's interpretation of it. This is a significant advantage when the FDA label supports coverage. The external-review window is approximately 4 months from the final internal denial.
• Expedited track: Request expedited review if the patient's condition is actively deteriorating.

## Documentation to Gather

1. Current FDA prescribing label: Download the most current version directly from the FDA's DailyMed database. Identify the exact indication language and the genotype/mutation classes covered. Confirm your patient's documented mutation appears within that language. 2. Genetic report with precise nomenclature: Use the same mutation naming convention as the FDA label. Discrepancies in nomenclature (e.g., common name vs. CFTR variant notation) can cause erroneous "not approved" flags. 3. Specialist confirmation letter: A CF specialist or pulmonologist should provide a written statement confirming that the patient's genotype falls within the FDA-approved population, citing the label section directly. 4. Aetna policy effective date vs. FDA approval date: If Aetna's policy predates a label expansion, document that gap. FDA approval supersedes a plan's internal policy that has not yet been updated.

## Criteria-Mapping Structure

| Denial Basis (from Aetna's letter) | Rebuttal Evidence | |---|---| | Mutation not listed in covered indication | FDA label section showing genotype coverage + genetic report | | Age outside approved population | FDA label age range + patient date of birth | | Policy effective date predates FDA expansion | FDA approval date documentation | | Nomenclature mismatch | Geneticist or CF specialist clarification letter |

The core of this appeal is documentary: place the FDA label language and the patient's genetic report side by side, with a clinician confirming they match. If Aetna's policy is outdated relative to the label, state that explicitly and note that the plan's contractual obligation tracks the FDA's determination, not an internal policy document that lags behind it.